Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

Clinical Infectious Diseases

Volumn 29, Issue 6, 1999, Pages 1402-1407

  Wingard, John R ^a   Kubilis, Paul ^b   Lee, Lily ^c   Yee, Gary ^b   White, Mary ^d   Walshe, Louise ^d   Bowden, Raleigh ^e   Anaissie, Elias ^f   Hiemenz, John ^g   Lister, John ^h  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Liposome Company Incorporated   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^g FLORIDA HOSPITAL   (United States)

^h W Pennsylvania Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CREATININE;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CREATININE; DRUG EVALUATION; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0033376314     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313498     Document Type: Article

References (26)

1. 1. Beck-Sague CM, Jarvis WR, the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167:1247-51.
2. 2. White MH, Bowden RA, Sandier ES, et al. Amphotericin B colloidal dispersion vs. amphotericin B in the empiric treatment of fever in neutropenic patients: a randomized, double-blind clinical trial. Clin Infect Dis 1998; 24:635-42.
3. 3. Llanos-Cuentas A, Cieza J, Echevarria J, et al. The safety and tolerance of amphotericin B lipid complex (ABLC) vs. amphotericin B deoxycholate (Fungizone [AB]) in patients with mucocutaneous leishmaniasis (MCL) [abstract 234]. In: Program and abstracts of the 32d Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim, CA). Washington, DC: American Society for Microbiology, 1992:149.
4. 4. Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immuno-compromised patients with hematologic malignancies. Bone Marrow Transplant 1997; 20:39-43.
5. 5. Anaissie EJ, White M, Uzun O, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract no LM21]. In: Program and abstracts of the 32d Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Washington, DC: American Society for Microbiology, 1995:330.
6. 6. Cagnoni PJ, Grethlein S, Korones DN, et al. Improved safety and efficacy of AmBisome (liposomal amphotericin B) compared with amphotericin B in the empirical treatment of febrile neutropenic patients undergoing bone marrow transplantation [abstract 1866]. Blood 1997;90(Suppl 1): 420a.
7. 7. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-8.
8. 8. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
9. 9. Goldstone AH, O'Driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 1994; 14(Suppl 5):S15-7.
10. 10. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Arch Intern Med 1995; 155:1093-8.
11. 11. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-71.
12. 12. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B [abstract 3383]. Blood 1995; 86(Suppl 1):849a.
13. 13. Butler WT, Bennett JT, Alling D, et al. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964; 61:175-87.
14. 14. Kennedy MS, Deeg HJ, Siegel M, et al. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983; 35:211-5.
15. 15. Clements JS Jr, Peacock JE Jr. Amphotericin B revisited; reassessment of toxicity. Am J Med 1990; 88:22N-7N.
16. 16. Gross MH, Pickard WW, Perfect JR. Retrospective review of amphotericin B use in a tertiary-care medical center. Am J Hosp Pharm 1987; 44:1353-7.
17. 17. Seabury JH, Dascomb HE. Experience with ampholericin B. Ann NY Acad Sci 1960; 89:202-20.
18. 18. Tynes BS, Utz JP, Bennett JE. Reducing amphotericin B reactions: a double-blind study. Am Rev Respir Dis 1963; 87:264-8.
19. 19. Sanford WG, Rasch JR, Stonehill RB. A therapeutic dilemma: the treatment of disseminated coccidioidomycosis with amphotericin B. Ann Intern Med 1962; 56:553-63.
20. 20. Miller RP, Bates JH. Amphotericin B toxicity: a follow-up report of 53 patients. Ann Intern Med 1969; 71:1089-95.
21. 21. Medoff G, Dismukes WE, Meade RHI, Moses JM. A new therapeutic approach to Candida infections: a preliminary report. Arch Intern Med 1972; 130:241-5.
22. 22. Grasela TH Jr, Goodwin SD, Walawander MK, Cramer RL, Fubs DW, Moriarty VP. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990; 10:341-8.
23. 23. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996; 101:170-6.
24. 24. Bodey GP, Anaissie EJ, Elting LS, et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994; 73:2099-106.
25. 25. Bearman SI, Appelbaum FR, Back A, et al. Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7:1288-94.
26. 26. Glynne P, Powles R, Steele J, et al. Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia. Acta Oncol 1996; 35:709-12.